Literature DB >> 1961113

Circulating immunoreactive endothelin in patients undergoing percutaneous transluminal coronary angioplasty.

A Tahara1, M Kohno, S Yanagi, H Itagane, I Toda, K Akioka, M Teragaki, M Yasuda, K Takeuchi, T Takeda.   

Abstract

Circulating immunoreactive endothelin (ir-ET) in the coronary sinus (CS) and the femoral artery (Ao) was measured in patients who underwent percutaneous transluminal coronary angioplasty (PTCA). Plasma ir-ET level in the CS was significantly increased from 1.6 +/- 0.8 pg/mL to 2.0 +/- 1.0 pg/mL after PTCA (P less than .05). Plasma ir-ET level in the Ao tended to increase after PTCA, but it was not significant. Plasma ir-ET level in the CS was not related to the plasma thromboglobulin level, plasma thrombin-antithrombin complex level, mean blood pressure, or heart rate. These results suggest that the increase of plasma ir-ET level in the CS may be associated with the coronary endothelial injury by PTCA.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1961113     DOI: 10.1016/0026-0495(91)90021-n

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  5 in total

1.  Does plasma endothelin during thrombolysis depend on infarct size? A pilot study.

Authors:  P Di Pasquale; S Paterna; G Parrinello; V Bucca; F Pipitone; G Tricoli; G Licata
Journal:  Cardiovasc Drugs Ther       Date:  1995-12       Impact factor: 3.727

Review 2.  The clinical potential of endothelin receptor antagonists in cardiovascular medicine.

Authors:  C J Ferro; D J Webb
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

3.  Peripheral vein plasma endothelin-1 levels during coronary angioplasty increase only in normotensive patients.

Authors:  Z S Kyriakides; M Markianos; E Iliodromitis; D Tsiapras; N Fragakis; D T Kremastinos
Journal:  Cardiovasc Drugs Ther       Date:  1994-10       Impact factor: 3.727

4.  Effects of captopril on plasma endothelin-1 during thrombolysis: preliminary findings.

Authors:  P Di Pasquale; S Paterna; G Parrinello; V Bucca; R Caracausi; F Pipitone; G Licata
Journal:  Cardiovasc Drugs Ther       Date:  1995-04       Impact factor: 3.727

Review 5.  Endothelin and myocardial ischemia.

Authors:  D Hasdai; R Kornowski; A Battler
Journal:  Cardiovasc Drugs Ther       Date:  1994-08       Impact factor: 3.727

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.